ETFIQData as of Nov 18, 2026. · etfiq.com/funds/fscs

FSCS Fact Sheet: First Trust SMID Capital Strength ETF

Share
$37.11
close, Nov 18, 2026

Over the year to Nov 18, 2026, FSCS returned +7.8% in total and charged 0.60% a year.

1-year total return
+7.8%
to Nov 18, 2026
Expense ratio
0.60%
a year
Net assets
$61m
on Nov 17, 2026
Net flow, last 5 trading days
$0
daily basis to Nov 17, 2026

Growth of $10,000, 1 year

FSCS $10,782 +7.8% · IWV $11,199 +12.0% · Total return, distributions reinvested, Nov 18, 2025 to Nov 18, 2026.

Returns

WindowTotal return
1 month+1.9%
3 months−2.2%
Year to date+4.8%
1 year+7.8%
3 years+36.0%
5 years+31.0%

Total return, distributions reinvested, each window to Nov 18, 2026.

Ten largest positions

HoldingWeight
Neurocrine Biosciences, Inc.1.20%
Hasbro, Inc.1.19%
Allegion Public Limited Company1.18%
Veralto Corporation1.16%
Healthcare Services Group, Inc.1.15%
Interparfums, Inc.1.13%
Jazz Pharmaceuticals Plc1.13%
ACI Worldwide, Inc.1.12%
Assurant, Inc.1.12%
Corpay, Inc.1.12%

FSCS top ten by weight, 11.5% of the fund, of its 100 equity positions, from the holdings published by its issuer for Nov 17, 2026.

Facts

Equity fund · Tracks the SMID Capital Strength Index · First traded Jun 22, 2017 · Benchmark Its own holdings, as of Nov 17, 2026

Source: ETFIQ, from issuer disclosures, SEC filings and exchange prices. Returns from daily closes, distributions reinvested; each number is dated beside it, and every one is on the fund’s page.Cite as: ETFIQ, FSCS Fact Sheet: First Trust SMID Capital Strength ETF. Data as of Nov 18, 2026. https://etfiq.com/funds/fscs/fact-sheet/ETFIQ is an independent publisher. Not an issuer, broker or adviser. No recommendations. Printed from etfiq.com/funds/fscs.